LB896 Mogamulizumab multimodality therapy with systemic retinoids, interferon, or extracorporeal photopheresis for advanced cutaneous t-cell lymphoma

The purpose of this study was to assess the clinical efficacy mogamulizumab in combination with systemic interferon, retinoids, and/or extracorporeal photopheresis for patients advanced cutaneous T-cell lymphoma. There are limited treatment options CTCL refractory previous therapies. At our center, has been combined other immunotherapies an enhanced synergistic effect these patients. This a retrospective case series on 11 (6 female; mean age 73 years) stage IIIB-IVB at University Pennsylvania Clinic who were treated multimodality regimen added interferon or without photopheresis. 9 achieved global response, 4 which complete response. Response rates by compartment 90% skin, 91% blood, and 50% lymph nodes. best skin involvement blood clonal cell count had decreased average 85% 74%, respectively. 8 remain progression after median follow-up 12.2 months. most common toxicities mogamulizumab-associated rash (n=6, 55%; grade 3: n=2, 18%), neutropenia lymphopenia n=3, 27%). managed based severity either observation, topical steroids, holding mogamulizumab. In conclusion, findings demonstrate that therapy offers highly effective approach CTCL. Further immunotherapy is warranted.